AVAX Provides Regulatory Update

Apr 23, 2001, 01:00 ET from AVAX Technologies, Inc.

    KANSAS CITY, Mo., April 23 /PRNewswire Interactive News Release/ -- AVAX
 Technologies, Inc. (Nasdaq:   AVXT) announced today that it has received written
 notifications from the U.S. Food and Drug Administration (FDA) confirming the
 previously-reported clinical hold of AVAX's M-Vax and O-Vax autologous cancer
 vaccine clinical trials.  The written notifications contain numerous FDA
 comments, questions and requests for additional information concerning the
 M-Vax and O-Vax products and clinical trials, and goes beyond the scope of
 prior oral communications from the FDA.  The FDA request for additional
 information, while including issues related to the sterility of tumor cells
 received by the Company also extends to the Company's handling of tumor cells,
 the preparation of vaccines by the Company and the Company's manufacturing
 practices.  Additionally, the FDA has begun an inspection of the Company's
 manufacturing facility in Philadelphia.
     The Company believes that it will take at least three months to prepare a
 comprehensive response to the clinical hold inquiries received from the FDA.
 Given that the Company does not yet know the results of the FDA site
 inspection, the Company cannot predict the timeframe for resolving any issues
 that arise from such inspection.  After a review of the Company's response,
 the FDA may have requests for additional information or clarifications from
 the Company.  Accordingly, the clinical hold cannot presently be characterized
 as temporary or short-term.
     Additionally, the Company notes that the FDA, in their notices, questions
 whether M-Vax and O-Vax are sufficiently developed for ongoing clinical trials
 to be considered adequate to support a biologics license application (BLA).
 The FDA notice includes a number of additional comments, questions and
 requests for additional information in order to resolve that issue.  In view
 of these developments, the Company cannot currently predict when it might be
 in a position to file a BLA for M-Vax.
     In a related matter, the Company announced that Ernest Yankee, Executive
 Vice President in charge of research and development, and Kamy Behzadi, Vice
 President of Operations, have resigned at the request of the Board of
 Directors.  The Company has experienced professionals in each of its
 Regulatory, Clinical Development and Manufacturing departments who continue to
 work diligently to address all of the FDA's concerns.
     The Company is continuing an internal review of its operations and
 technologies.  To that end, and as a result of the oral notification of the
 FDA clinical hold for the M-Vax and O-Vax trials, the Company has retained a
 strategic consulting services firm with extensive experience in new drug
 development and commercialization to assist the Company in an expeditious
 completion of this review.
     Except for statements that are historical, the statements in this release
 are "forward-looking" statements that are made pursuant to the safe harbor
 provisions of Section 27A of the Securities Act of 1933 and Section 21E of the
 Securities Exchange Act of 1934.  Forward-looking statements involve
 significant risks and uncertainties, and in light of the significant
 uncertainties inherent in such statements, the inclusion of such information
 should not be regarded as a representation by AVAX that the objectives and
 plans of the company will be achieved.  In fact, actual results could differ
 materially from those contemplated by such forward-looking statements.  Many
 important factors affect the Company's prospects, including, the results of
 the current FDA clinical hold for the M-Vax and O-Vax clinical trials and
 other FDA questions regarding those products, the results of the FDA's ongoing
 inspection of the Company's manufacturing facility, the Company's ability to
 obtain substantial additional funds, to obtain and maintain all necessary
 patents or licenses, to demonstrate the safety and efficacy of product
 candidates at each stage of development, to meet applicable regulatory
 standards and receive required regulatory approvals, to meet obligations and
 required milestones under its license agreements, to be capable of producing
 drug candidates in commercial quantities at reasonable costs, to compete
 successfully against other products, and to market products in a profitable
 manner, as well as other risks detailed from time to time in AVAX's public
 disclosure filings with the Securities and Exchange Commission, including,
 without limitation, its Annual Report on Form 10-KSB for the fiscal year ended
 December 31, 2000.  AVAX does not undertake any obligation to publicly release
 any revisions to these forward-looking statements or to reflect the occurrence
 of unanticipated events.
 
     CONTACT:  David Tousley of AVAX Technologies, Inc., 816-960-1333.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X58230561
 
 

SOURCE AVAX Technologies, Inc.
    KANSAS CITY, Mo., April 23 /PRNewswire Interactive News Release/ -- AVAX
 Technologies, Inc. (Nasdaq:   AVXT) announced today that it has received written
 notifications from the U.S. Food and Drug Administration (FDA) confirming the
 previously-reported clinical hold of AVAX's M-Vax and O-Vax autologous cancer
 vaccine clinical trials.  The written notifications contain numerous FDA
 comments, questions and requests for additional information concerning the
 M-Vax and O-Vax products and clinical trials, and goes beyond the scope of
 prior oral communications from the FDA.  The FDA request for additional
 information, while including issues related to the sterility of tumor cells
 received by the Company also extends to the Company's handling of tumor cells,
 the preparation of vaccines by the Company and the Company's manufacturing
 practices.  Additionally, the FDA has begun an inspection of the Company's
 manufacturing facility in Philadelphia.
     The Company believes that it will take at least three months to prepare a
 comprehensive response to the clinical hold inquiries received from the FDA.
 Given that the Company does not yet know the results of the FDA site
 inspection, the Company cannot predict the timeframe for resolving any issues
 that arise from such inspection.  After a review of the Company's response,
 the FDA may have requests for additional information or clarifications from
 the Company.  Accordingly, the clinical hold cannot presently be characterized
 as temporary or short-term.
     Additionally, the Company notes that the FDA, in their notices, questions
 whether M-Vax and O-Vax are sufficiently developed for ongoing clinical trials
 to be considered adequate to support a biologics license application (BLA).
 The FDA notice includes a number of additional comments, questions and
 requests for additional information in order to resolve that issue.  In view
 of these developments, the Company cannot currently predict when it might be
 in a position to file a BLA for M-Vax.
     In a related matter, the Company announced that Ernest Yankee, Executive
 Vice President in charge of research and development, and Kamy Behzadi, Vice
 President of Operations, have resigned at the request of the Board of
 Directors.  The Company has experienced professionals in each of its
 Regulatory, Clinical Development and Manufacturing departments who continue to
 work diligently to address all of the FDA's concerns.
     The Company is continuing an internal review of its operations and
 technologies.  To that end, and as a result of the oral notification of the
 FDA clinical hold for the M-Vax and O-Vax trials, the Company has retained a
 strategic consulting services firm with extensive experience in new drug
 development and commercialization to assist the Company in an expeditious
 completion of this review.
     Except for statements that are historical, the statements in this release
 are "forward-looking" statements that are made pursuant to the safe harbor
 provisions of Section 27A of the Securities Act of 1933 and Section 21E of the
 Securities Exchange Act of 1934.  Forward-looking statements involve
 significant risks and uncertainties, and in light of the significant
 uncertainties inherent in such statements, the inclusion of such information
 should not be regarded as a representation by AVAX that the objectives and
 plans of the company will be achieved.  In fact, actual results could differ
 materially from those contemplated by such forward-looking statements.  Many
 important factors affect the Company's prospects, including, the results of
 the current FDA clinical hold for the M-Vax and O-Vax clinical trials and
 other FDA questions regarding those products, the results of the FDA's ongoing
 inspection of the Company's manufacturing facility, the Company's ability to
 obtain substantial additional funds, to obtain and maintain all necessary
 patents or licenses, to demonstrate the safety and efficacy of product
 candidates at each stage of development, to meet applicable regulatory
 standards and receive required regulatory approvals, to meet obligations and
 required milestones under its license agreements, to be capable of producing
 drug candidates in commercial quantities at reasonable costs, to compete
 successfully against other products, and to market products in a profitable
 manner, as well as other risks detailed from time to time in AVAX's public
 disclosure filings with the Securities and Exchange Commission, including,
 without limitation, its Annual Report on Form 10-KSB for the fiscal year ended
 December 31, 2000.  AVAX does not undertake any obligation to publicly release
 any revisions to these forward-looking statements or to reflect the occurrence
 of unanticipated events.
 
     CONTACT:  David Tousley of AVAX Technologies, Inc., 816-960-1333.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X58230561
 
 SOURCE  AVAX Technologies, Inc.